Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
FAQ
- What is Kymera Therapeutics's EBIT?
- Kymera Therapeutics (KYMR) reported EBIT of -$75.61M in Q2 2026.
- How has Kymera Therapeutics's EBIT changed year-over-year?
- Kymera Therapeutics's EBIT increased by 10.6% year-over-year, from -$84.56M to -$75.61M.
- What is the long-term trend for Kymera Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Kymera Therapeutics's EBIT has grown at a 36.5% compound annual growth rate (CAGR), from -$100.53M to -$349.4M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Kymera Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude